Jun. 3 at 6:06 PM
$CHRS 2/2
Investors will be paying close attention to:
• Confirmation that clinical programs continue to advance.
• Management’s confidence during the presentation and Q&A session.
• Any positive commentary regarding CCR8 or IL-27.
• Any indication of strategic interest, partnerships, or future opportunities.
Of course, if the presentation simply repeats previously disclosed information without providing anything new, the market reaction could be limited.
However, the fact that the CEO is presenting at Jefferies immediately following ASCO sends an important message: CHRS is still actively promoting its investment story and continues to believe in the value of its pipeline and long-term strategy. For that reason alone, this event may prove far more important than the daily noise from bulls and bears on Stocktwits.
